SLAMF6 and B-cell non-Hodgkin lymphoma: To evaluate whether αSlamf6 would also effectively remove an unrelated CD19+B220+ murine B cell lymphoma, LMP2A/λMyc [35], which expresses Slamf6 (Figure 2A), on day 7 and 14 after i.p injection of LMP2A/λMyc [1 × 106 cells/mouse] into Rag1−/− mice, 200μg/mouse αSlamf6 or isotype control was administered (Figure 2B).